Genitourinary SACT Regimens

Regimen

Indication

00450a

Treatment of muscle invasive bladder cancer in patients.

Regimen

Indication

00544b

Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing chemotherapy

00544c

Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥5%

Regimen

Indication

00593b

Treatment of adult patients with locally advanced or metastatic

urothelial carcinoma (mUC) after prior platinum-containing

chemotherapy

00593c

Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥5%

Regimen

Indication

00535b

First-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum based chemotherapy

Regimen

Indication

00807a

Non-Muscle Invasive Bladder Cancer – very high risk, high risk and intermediate risk groups

Regimen

Indication

00385b

Chemoradiation treatment for locally advanced bladder cancer.

Regimen

Indication

00337a

Neoadjuvant treatment of muscle invasive transitional cell carcinoma (TCC) of the urothelium.

Regimen

Indication

00885a

As monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.

Regimen

Indication

00846a

For the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 (PD-1) or programmed death ligand 1 inhibitor (PD-L1).

Regimen

Indication

00945a

First-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy

Regimen

Indication

00759a

Treatment of muscle-invasive transitional cell urothelial bladder cancer

Regimen

Indication

00310a

Treatment of patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium where CISplatin is contraindicated*

Regimen

Indication

00622a

Treatment of patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium in patients with impaired renal function

Regimen

Indication

00628a

Adjuvant treatment of upper tract urothelial carcinoma

Regimen

Indication

00282a

Treatment of patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium

Regimen

Indication

00894a

BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC)

00894b

Patients with high risk NMIBC who are intolerant of or ineligible for intravesical BCG

Regimen

Indication

00333a

Locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium.

Regimen

Indication

00338a

Neoadjuvant treatment of muscle invasive transitional cell carcinoma (TCC) of the urothelium.

00338b

Adjuvant treatment of muscle invasive TCC of the urothelium.

00338c

Locally advanced or metastatic TCC of the urothelium.

Regimen

Indication

00483h

As monotherapy for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥1%, who are at high risk of recurrence after undergoing radical resection of MIUC, providing patients are unsuitable for adjuvant treatment with platinum based chemotherapy.

Regimen

Indication

00484h

As monotherapy for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥1%, who are at high risk of recurrence after undergoing radical resection of MIUC, providing patients are unsuitable for adjuvant treatment with platinum-based chemotherapy.

Regimen

Indication

00226e*

Second line chemotherapy for metastatic bladder cancer

Regimen

Indication

00621e*

Second line chemotherapy for metastatic bladder cancer

Regimen

Indication

00455e

As monotherapy for the treatment of locally advanced or metastatic urothelialcarcinoma in adults who have received prior platinum-containing chemotherapy

Regimen

Indication

00455f

As monotherapy is indicated for the treatment of locally advanced or metastaticurothelial carcinoma in adults who are not eligible for cisplatin-containingchemotherapy whose tumours express PD-L1 with a combined positive score (CPS)≥10

Regimen

Indication

00558e

As monotherapy for the treatment of locally advanced or metastatic urothelialcarcinoma in adults who have received prior platinum-containing chemotherapy

00558f

As monotherapy is indicated for the treatment of locally advanced or metastaticurothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy whose tumours express PD-L1 with a combined positive score (CPS)≥10

Regimen

Indication

00300a

Adjuvant treatment of high risk (vascular invasion carcinoma) stage 1 nonseminoma germ cell tumour.

00300b

Metastatic germ cell tumours of the testis.

00300c

Advanced stage or metastatic germ cell tumours (dysgermimoma) of the ovaries.

00300d

Extra-gonadal germ cell tumours.

Regimen

Indication

00453a

Treatment of metastatic relapsed/refractory germ cell tumours.

Regimen

Indication

00301a

Treatment of good prognosis (IGCCCG criteria) metastatic germ cell tumours (both non-seminoma and seminoma).

Regimen

Indication

00602a

Treatment of relapsed / refractory metastatic testicular germ cell cancer

Regimen

Indication

00103a

Abiraterone is indicated in combination with predniSONE or prednisoLONE for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

00103b

Treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated

Regimen

Indication

00577a

Abiraterone is indicated with predniSONE or prednisoLONE for:

the treatment of newly diagnosed high risk metastatic hormone sensitive

prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)

Regimen

Indication

00574a

Apalutamide is indicated for the treatment of adult men with nonmetastaticcastration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.

00574b

For the treatment of patients with metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.

Regimen

Indication

00482a

Treatment of advanced prostate cancer in combination with luteinizing-hormone releasing hormone (LHRH) analogue therapy or surgical castration

Regimen

Indication

00101a

Cabazitaxel is indicated in combination with predniSONE or prednisoLONE for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen

Regimen

Indication

00693a

Treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.

Regimen

Indication

00481a

Treatment of adult male patients with advanced hormone-dependent prostate cancer

Regimen

Indication

00546a

In combination with predniSONE or prednisoLONE is indicated for the treatment of patients with hormone refractory metastatic prostate cancer

Regimen

Indication

00313a

In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

Regimen

Indication

00203b

First line in high risk non metastic castration sensitive prostate cancer.

00203c

First line in metastatic castration sensitive prostate cancer.

Regimen

Indication

00233a

Treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

00233b
Treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

00233c

The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC)

Regimen

Indication

00477a

Treatment of locally advanced or metastatic hormone sensitive prostate cancer

Regimen

Indication

00478a

Treatment of locally advanced or metastatic hormone sensitive prostate cancer

Regimen

Indication

00492a

Management of prostatic carcinoma for which a suppression of testosterone is indicated

Regimen

Indication

00479a

Treatment of hormone dependent advanced prostate cancer

00479b

Treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy

Regimen

Indication

00494a

Management of prostatic carcinoma for which a suppression of testosterone is indicated

Regimen

Indication

00493a

Treatment of locally advanced or metastatic hormone dependent advanced prostate cancer

Regimen

Indication

00491a

Treatment of hormone dependent advanced prostate cancer

00491b

Treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy

Regimen

Indication

00490a

Treatment of hormone dependent advanced prostate cancer

00490b

Treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy

Regimen

Indication

00848a

Niraparib in combination with abiraterone acetate (Akeega®) and predniSONE/prednisoLONE for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated

Regimen

Indication

00588g

As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.

Regimen

Indication

00257a

As monotherapy or in combination with LHRH analogues for the treatment of adults with progressive castration-resistant metastatic prostate cancer (mCRPC, symptomatic bone metastases and no extensive visceral metastases after at least two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available licensed systemic mCRPC treatment

Regimen

Indication

00830a

Treatment of adult patients with advanced hormone-sensitive prostate cancer (HSPC).

Regimen

Indication

00480a

Treatment of locally advanced or metastatic hormone dependent advanced prostate cancer

Regimen

Indication

00488a

Treatment of locally advanced or metastatic hormone dependent advanced prostate cancer

Regimen

Indication

00489a

Treatment of locally advanced or metastatic hormone dependent advanced prostate cancer

Regimen

Indication

00104a

Treatment of adult patients with advanced RCC after failure, on a previous line of therapy, i.e. treatment with SUNItinib, or a cytokine.

Regimen

Indication

00592a

Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.

00592b

Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing chemotherapy.

00592c

Treatment of adult patients with locally advanced or metastatic

urothelial carcinoma (UC) who are considered cisplatin ineligible and

whose tumours have a PD-L1 expression ≥5%.

Regimen

Indication

00212d

In combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.

Regimen

Indication

00518a

Treatment of advanced renal cell carcinoma (RCC) in adults following prior VEGF targeted therapy

Regimen

Indication

00320a

Treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.

Regimen

Indication

00588c

Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) primary peritoneal carcinoma who are in response (complete or partial) following completion of first‐line platinum based chemotherapy

00588f

Maintenance treatment of adult patients with platinum -sensitive relapsed BRCA-mutated (germline and/or somatic) primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.

Regimen

Indication

00483b

As monotherapy for the treatment of advanced renal cell carcinoma (RCC) after prior therapy in adults.

Regimen

Indication

00484b

As monotherapy for the treatment of advanced renal cell carcinoma (RCC) after prior therapy in adults.

Regimen

Indication

00551a

Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).

Regimen

Indication

00445a

First line treatment of advanced Renal Cell Carcinoma (RCC) in adults and for patients who have received prior cytokine therapy for advanced disease.

Regimen

Indication

00455m

For the adjuvant treatment of adult patients with renal cell carcinoma (RCC) at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Regimen

Indication

00558m

For the adjuvant treatment of adult patients with renal cell carcinoma (RCC) at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Regimen

Indication

00583a

Pembrolizumab in combination with axitinib for the first-line treatment ofadvanced renal cell carcinoma (RCC) in adults.

Regimen

Indication

00294b

Treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Regimen

Indication

00325b

Treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults

Regimen

Indication

00719b

Treatment of clear-cell type metastatic renal cell carcinoma (MRCC).

Regimen

Indication

00326a

First-line treatment of adult patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors.

Regimen

Indication

00564a

Tivozanib for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC